TY - JOUR
T1 - Identification of coinfections by viral and bacterial pathogens in covid-19 hospitalized patients in peru
T2 - Molecular diagnosis and clinical characteristics
AU - Pérez-Lazo, Giancarlo
AU - Silva-Caso, Wilmer
AU - Del Valle-Mendoza, Juana
AU - Morales-Moreno, Adriana
AU - Ballena-López, José
AU - Soto-Febres, Fernando
AU - Martins-Luna, Johanna
AU - Carrillo-Ng, Hugo
AU - Del Valle, Luís J.
AU - Kym, Sungmin
AU - Aguilar-Luis, Miguel Angel
AU - Peña-Tuesta, Issac
AU - Tinco-Valdez, Carmen
AU - Illescas, Luis Ricardo
N1 - Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.
PY - 2021/11
Y1 - 2021/11
N2 - The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.
AB - The impact of respiratory coinfections in COVID-19 is still not well understood despite the growing evidence that consider coinfections greater than expected. A total of 295 patients older than 18 years of age, hospitalized with a confirmed diagnosis of moderate/severe pneumonia due to SARS-CoV-2 infection (according to definitions established by the Ministry of Health of Peru) were enrolled during the study period. A coinfection with one or more respiratory pathogens was detected in 154 (52.2%) patients at hospital admission. The most common coinfections were Mycoplasma pneumoniae (28.1%), Chlamydia pneumoniae (8.8%) and with both bacteria (11.5%); followed by Adenovirus (1.7%), Mycoplasma pneumoniae/Adenovirus (0.7%), Chlamydia pneumoniae/Adenovirus (0.7%), RSV-B/Chlamydia pneumoniae (0.3%) and Mycoplasma pneumoniae/Chlamydia pneumoniae/Adenovirus (0.3%). Expectoration was less frequent in coinfected individuals compared to non-coinfected (5.8% vs. 12.8%). Sepsis was more frequent among coinfected patients than non-coinfected individuals (33.1% vs. 20.6%) and 41% of the patients who received macrolides empirically were PCR-positive for Mycoplasma pneumoniae and Chlamydia pneumoniae.
KW - Antibiotics
KW - COVID-19
KW - Coinfections
UR - https://www.scopus.com/pages/publications/85118939573
U2 - 10.3390/antibiotics10111358
DO - 10.3390/antibiotics10111358
M3 - Artículo
AN - SCOPUS:85118939573
SN - 2079-6382
VL - 10
JO - Antibiotics
JF - Antibiotics
IS - 11
M1 - 1358
ER -